The FDA's acceptance and priority review of a BLA is a significant positive regulatory milestone for any biotech company, often leading to increased investor confidence and a rise in stock price. For PTC Therapeutics, this development directly impacts the company's valuation and investor perception, as it moves closer to potentially bringing a new product to market.